Disc Medicine, Inc. - 8-K Filing
Disc Medicine's APOLLO Phase 3 trial of bitopertin met all primary and secondary endpoints for EPP/XLP, with plans to resubmit an NDA by year-end. (Items: 7.01 Regulation FD Disclosure, 8.01 Other Events, 9.01 Exhibits)
Tickers: $IRON
Read the full article at SEC EDGAR
Part of the story Mirum Pharmaceuticals, Inc. - 8-K Filing (7 articles)